Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rovalpituzumab tesirine

- PMLiVE

PD1 drugs could end ‘decades of silence’ in bladder cancer therapy

Merck's Keytruda and Roche antibody showing promise

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

- PMLiVE

Humira gets FDA nod for paediatric Crohn’s disease

Can be used as treatment for patients as young as six

- PMLiVE

Iressa blood test nears approval in Europe

Diagnostic for AZ's lung cancer drug is less invasive than current tumour biopsy method

- PMLiVE

The M&A trend in pharma

Are pharma deals back in fashion or is big pharma in retreat and needing to reshape

Boehringer Ingelheim headquarters

Boehringer signs €465m lung cancer vaccine deal

Licenses CureVac's cancer immunotherapy CV9202

- PMLiVE

Merck Serono pulls development of lung cancer prospect

Ditches tecemotide immunotherapy to focus on anti-PD1

- PMLiVE

Pre-chemotherapy indication for Xtandi in prostate cancer

Astellas drug set to compete with J&J’s Zytiga

- PMLiVE

Pharma spent $342m on journal advertising in first half of 2014

J&J led spending and Invokana was most advertised brand

Pharma deals during August 2014

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month

Deal Watch table for August 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links